Clinical Trial Update: Adalimumab on Preventing Post-chirurgic Recurrence on Crohn´s Disease [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating adalimumab for preventing postoperative recurrence in Crohn's disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• ADALIMUMAB (ADALIMUMAB-AATY)

Snippet

Sponsor: Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa | Conditions: Crohn´s Disease | Phase 3 | Status: COMPLETED